OBJECTIVES Health economic evaluations (EE) and budget impact analysis (BIA) for pharmaceuticals are increasingly being used for decision making. Guidelines can be very useful to help authors with the use of proper methodology, assess the quality and optimise the reporting of such evaluations. To our knowledge, there are no such published guidelines in Spain. METHODS This guidance was designed with the main aim of providing authors with recommendations, in the form of a checklist, to optimise design and reporting of EE and BIA to be submitted to the Catalan Health System (CatSalut) within its harmonization program for pharmaceutical innovation. RESULTS For a given evaluation, two separate guidelines with corresponding checklists assess its methodology, quality, and reporting based on several dimensions. CONCLUSIONS The steps outlined in this first guidance in Spain, although not compulsory, will provide useful practical tips for how to go about designing and reporting of an EE or a BIA for pharmaceuticals in Catalonia (Spain).